Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Nvs crawled time : 13:00 save search
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
Published: 2024-02-14 (Crawled : 13:00) - globenewswire.com
ERAS | $1.795 -2.45% -2.51% 650K
|
|
| O: 2.99%
H: 2.03%
C: 0.58%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.02%
H: 0.24%
C: 0.01%
trials collaboration trial
Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)
Published: 2024-01-11 (Crawled : 13:00) - globenewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.22%
H: 0.43%
C: 0.37%
LNTH | News | $62.34 1.4% 1.38% 1.3M
|
Health Technology
|
| O: 0.32%
H: 0.03%
C: -4.42%
lutathera
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
Published: 2023-12-11 (Crawled : 13:00) - globenewswire.com
ERAS | $1.795 -2.45% -2.51% 650K
|
|
| O: 1.07%
H: 0.0%
C: -2.65%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.75%
H: 0.55%
C: 0.27%
fda melanoma granted designation advanced
Dyadic Appoints Doug Pace to Its Executive Leadership Team
Published: 2023-10-09 (Crawled : 13:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.21%
H: 1.24%
C: 0.42%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.01%
H: 0.47%
C: 0.45%
DYAI A | $1.605 -4.46% -4.67% 37K
|
Health Technology
|
| O: -2.45%
H: 0.0%
C: -2.01%
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
Published: 2023-10-03 (Crawled : 13:00) - biospace.com/
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
|
| O: 2.22%
H: 0.87%
C: -0.65%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -1.6%
H: 0.36%
C: -0.46%
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: 0.1%
H: 0.74%
C: -1.67%
xolair biosimilar commercialization agreement
Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer
Published: 2023-09-27 (Crawled : 13:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.99%
H: 0.0%
C: 0.0%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.13%
H: 0.06%
C: -1.02%
CERS | News | $1.645 0.31% 0.3% 760K
|
Health Technology
|
| O: -1.3%
H: 5.92%
C: 0.66%
corporation
Sandoz signs Memorandum of Understanding to build new biologics production plant in Slovenia, to support increasing global demand for biosimilar medicines
Published: 2023-03-09 (Crawled : 13:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -5.6%
H: 1.19%
C: 1.19%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -3.04%
H: 0.16%
C: -0.9%
global biosimilar
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
Published: 2023-02-07 (Crawled : 13:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 2.27%
H: 0.0%
C: 0.0%
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.13%
H: 1.01%
C: 0.89%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.29%
H: 0.86%
C: 0.72%
XNCR | $18.98 -0.47% -0.47% 470K
|
Health Technology
|
| O: -0.19%
H: 1.15%
C: -2.27%
MOR | $18.02 -0.11% -0.11% 590K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -0.59%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -1.02%
H: 0.29%
C: -3.04%
financial
Global Precision Medicine Market Competitive Landscape and Trends - By The Business Research Company
Published: 2023-01-31 (Crawled : 13:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.75%
H: 0.0%
C: -1.15%
TMO | News | $541.52 -1.05% 0.61% 2.1M
|
Health Technology
|
| O: -0.37%
H: 1.5%
C: 1.45%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.09%
H: 1.19%
C: 1.18%
MDT | $79.19 0.14% 0.0% 6.1M
|
Health Technology
|
| O: 0.21%
H: 1.16%
C: 1.14%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
research global trends market
Dr. Reddy's Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market
Published: 2023-01-27 (Crawled : 13:00) - biospace.com/
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.56%
H: 0.73%
C: 0.17%
market ophthalmic emulsion
The Worldwide Lysosomal Disease Treatment Industry is Expected to Reach $11 Billion by 2028
Published: 2023-01-13 (Crawled : 13:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.13%
H: 0.76%
C: 0.76%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 2.77%
H: 0.63%
C: 0.63%
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.13%
H: 2.35%
C: 2.16%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.44%
H: 1.39%
C: 0.74%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.15%
H: 0.65%
C: 0.4%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.47%
H: 0.47%
C: 0.14%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.13%
H: 1.04%
C: 0.57%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
BMRN S | $90.08 -0.43% -0.43% 940K
|
Health Technology
|
| O: -1.16%
H: 2.27%
C: 0.42%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 1.27%
H: 0.78%
C: 0.15%
treatment disease expected
Outlook on the Pharmaceutical Drugs Global Market to 2027: Look at the Changing Structure of the Pharma and Healthcare Industry
Published: 2023-01-03 (Crawled : 13:00) - prnewswire.com
ENDPQ | $0.0006 -50.0% 620K
|
n/a
|
| O: -1.13%
H: 28.57%
C: 19.0%
CSLLY | $87.96 3.3% 45K
|
n/a
|
| O: -3.93%
H: 2.17%
C: 1.75%
MNK | $0.3402 -0.06% 540K
|
n/a
|
| O: 3.1%
H: 0.0%
C: -2.75%
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -0.2%
H: 2.06%
C: 2.06%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.09%
H: 0.54%
C: 0.54%
UCBJY | $64.07 -4.38% 72K
|
Manufacturing
|
| O: 1.0%
H: 0.0%
C: -0.26%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 3.43%
H: 0.0%
C: -2.93%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: 0.54%
H: 2.5%
C: 1.7%
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 1.43%
H: 0.84%
C: -0.23%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.42%
H: 1.35%
C: 1.22%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.28%
H: 1.26%
C: 1.15%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.57%
H: 1.35%
C: 1.0%
BHC | $8.6 -0.69% 0.0% 2.1M
|
Health Technology
|
| O: 0.48%
H: 3.96%
C: -0.48%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.27%
H: 0.6%
C: 0.21%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.67%
H: 0.66%
C: 0.3%
pharma global market
Cell Therapy Market Value to Reach US$ 54.6 Bn by 2032, States TMR Study
Published: 2022-12-19 (Crawled : 13:00) - prnewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.0%
H: 0.09%
C: -0.32%
VCEL | $43.86 -5.19% -5.47% 430K
|
Health Technology
|
| O: -0.49%
H: 0.02%
C: -6.55%
therapy study market
Outlook on the Age-related Macular Degeneration Global Market to 2030 - Players Include Bayer, Pfizer, Bausch Health and Amgen Among Others
Published: 2022-12-14 (Crawled : 13:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.74%
H: 0.45%
C: -1.8%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 1.0%
H: 1.29%
C: 0.45%
BHC | $8.6 -0.69% 0.0% 2.1M
|
Health Technology
|
| O: -0.39%
H: 3.26%
C: 2.34%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.11%
H: 0.51%
C: -0.31%
global macular health market
Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
Published: 2022-12-09 (Crawled : 13:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.55%
H: 0.39%
C: 0.39%
ERAS | $1.795 -2.45% -2.51% 650K
|
|
| O: -9.03%
H: 0.75%
C: -14.59%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.24%
H: 0.32%
C: -0.93%
license
The Worldwide Diabetic Retinopathy Industry is Expected to Reach $7.7 Billion by 2027 at a 11.3% CAGR
Published: 2022-11-22 (Crawled : 13:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.33%
H: 1.88%
C: 1.53%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.77%
H: 0.41%
C: 0.27%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.66%
H: 0.79%
C: 0.72%
ALIM | $3.4 -4.23% -4.41% 57K
|
Health Technology
|
| O: 0.47%
H: 7.5%
C: -1.17%
expected diabetic
Seagen Names David R. Epstein as Chief Executive Officer and Director
Published: 2022-11-10 (Crawled : 13:00) - biospace.com/
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 2.81%
H: 0.43%
C: -0.2%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: -1.69%
H: 0.1%
C: -3.37%
Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Published: 2022-11-08 (Crawled : 13:00) - biospace.com/
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.54%
H: 1.08%
C: 0.57%
SWTX | News | $42.48 -3.7% -3.84% 810K
|
Health Technology
|
| O: 1.64%
H: 4.18%
C: -1.53%
DTIL | $10.77 -6.43% -6.87% 71K
|
Health Technology
|
| O: -0.81%
H: 6.5%
C: 3.25%
financial update results
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala® (mepolizumab) Bio-Thera Solutions, Ltd. announced that dosing has begun in a Phase I cli...
Published: 2022-10-14 (Crawled : 13:00) - biospace.com/
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.17%
H: 0.8%
C: -0.75%
MS | News 0 d | $90.26 0.2% 0.0% 6.7M
|
Finance
|
| O: -2.63%
H: 2.37%
C: -2.5%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 1.93%
H: 0.0%
C: 0.0%
DVA | $126.11 -1.2% 0.0% 750K
|
Health Services
|
| O: 0.65%
H: 1.88%
C: -0.77%
VRNA | $16.1 -1.83% -1.86% 490K
|
Health Technology
|
| O: 0.4%
H: 1.39%
C: -0.3%
UTHR | $237.16 0.79% 0.78% 480K
|
Health Technology
|
| O: 0.24%
H: 1.71%
C: 1.01%
NNVC | $1.175 1.29% 0.0% 13K
|
Health Technology
|
| O: 2.34%
H: 0.0%
C: 0.0%
bat2606 nucala solutions biosimilar study
Fulgent Genetics Welcomes Dr. Michael Nohaile and Dr. Leonard Post to Board of Directors
Published: 2022-08-04 (Crawled : 13:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -2.88%
H: 0.0%
C: -0.21%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.2%
H: 0.44%
C: 0.24%
QURE | $4.71 0.86% 0.85% 440K
|
Health Technology
|
| O: 1.32%
H: 1.12%
C: 0.34%
FLGT | $20.12 0.15% 0.15% 220K
|
Health Services
|
| O: 0.43%
H: 3.12%
C: 0.85%
BMRN S | $90.08 -0.43% -0.43% 940K
|
Health Technology
|
| O: 1.7%
H: 4.68%
C: 3.43%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.06%
H: 0.81%
C: -0.01%
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.